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Photodynamic effectThemitochondrial permeability transition is an increase of permeability of the innermitochondrial membrane
to ions and solutes with an exclusion size of about 1500 Da. It is generally accepted that the permeability
transition is due to opening of a high-conductance channel, the permeability transition pore. Although the
molecular nature of the permeability transition pore remains undeﬁned, a great deal is known about its
regulation and role in pathophysiology. This review speciﬁcally covers the characterization of the permeability
transition pore by chemical modiﬁcation of speciﬁc residues through photoirradiation of mitochondria after
treatment with porphyrins. The review also illustrates the basic principles of the photodynamic effect and the
mechanisms of phototoxicity and discusses the unique properties of singlet oxygen generated by speciﬁc
porphyrins in discrete mitochondrial domains. These experiments provided remarkable information on the
role, interactions and topology of His and Cys residues in permeability transition poremodulation and deﬁned
an important role for the outer membrane 18 kDa translocator protein (formerly known as the peripheral
benzodiazepine receptor) in regulation of the permeability transition.; CP, coproporphyrin III; CRC,
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The mitochondrial permeability transition (PT) is an increase of
permeability of the inner mitochondrial membrane (IMM) to ions and
solutes with an exclusion size of about 1500 Da [1–4]. The prevailing
view is that the PT is due to opening of a regulated protein channel, the
PTpore (PTP),which in the fully open state has anestimateddiameter of
about 3 nm [3,5]. PTP opening requires the presence of matrix [Ca2+],which is an essential permissive factor, and of additional agents or
conditions that are collectively termed “inducers” [6–15]. In spite of
major efforts themolecular nature of the PTP remains undeﬁned. Earlier
candidates such as the IMM adenine nucleotide translocator (ANT) and
the outer mitochondrial membrane (OMM) VDAC appear to be
regulators rather than constituents of the PTP, as their genetic ablation
did not prevent PTP opening [16–18] nor its sensitivity to cyclosporin A
(CsA) [19–22], a high-afﬁnity inhibitor of cyclophilins (CyP) that
desensitizes the PTP to the inducing effects of Ca2+ and Pi through its
binding to matrix CyPD [23–25]. Consistent with these ﬁndings, recent
work has shown that the polyclonal antibody used to identify a CyPD-
binding protein as ANT1 in fact labeled the Pi carrier, which has now
been incorporated in the model of the PTP proposed by the Halestrap
laboratory [12,26].
Ablation of the Ppif gene encoding CyPD has similar effects as CsA,
in the sense that a higher of Ca2+ load and Pi is required for PTP
opening in isolated mitochondria [27–30]. Pi is a classical inducer of
the PTP, but we recently found that CyPD inhibition or its genetic
ablation sensitizes the pore to the inhibitory effects of Pi, which would
be the actual inhibitor of the pore under these conditions [31]. The
evolutionary implications of this ﬁnding and their importance in
reevaluating the yeast PTP (which is inhibited by Pi) as amodel for the
mammalian pore have been discussed in greater detail elsewhere [32].
1.1. The PTP as a fast Ca2+ release channel
Transient pore openings occur both in isolated mitochondria [33]
and in situ [34], and we have proposed that the PTP could serve a
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This hypothesis is consistent with early results on the effects of CsA in
Ca2+ distribution in rat ventricular cardiomyocytes [36] and with
recent ﬁndings in Ppif−/− mice whose heart mitochondria display a
2.6-fold elevation in total Ca2+ levels and consequent activation of
intramitochondrial Ca2+-dependent dehydrogenases resulting in
stimulation of glucose oxidation at the expense of fatty acids [37].
Strikingly, CyPD ablation resulted in increased propensity to heart
failure after transaortic constriction, overexpression of Ca2+/calmod-
ulin-dependent protein kinase IIδc and swimming exercise [37],
ﬁndings that suggest a progressive Ca2+ overload due to decreased
probability of PTP opening. That the PTP may serve as a physiological
Ca2+ release channel is also supported by recent work in mouse
primary adult neurons showing that PTP is activated in response to the
combined action of more than one physiological stimulus affecting
cytosolic [Ca2+] and that under these conditions PTP opening does not
induce neuronal death but rather takes part in physiological Ca2+
dynamics [38].
1.2. Role of the PTP in disease
The role of the PTP as a mediator of cell death in paradigms
relevant to human health is no longer questioned. A word of
caution about an exclusive causative role of the pore is in order
about early studies based on the effects of CsA alone because (i)
inhibition of calcineurin prevents mitochondrial ﬁssion by inhibiting
mitochondrial translocation of Drp1, a cytoprotective event that
occurs independent of PTP inhibition [39]; and (ii) CyPD displays
multiple regulatory interactions in mitochondria including CsA-
sensitive binding to Hsp90 and TRAP1 [40], modulation of the FOF1
ATP synthase [41] and binding to Bcl2 [42] (see Ref. [43] for a
review). Yet a role of the PTP is generally supported by studies of
Ppif−/− mice and of their cross-breeding with several disease
genotypes.
Ppif−/− mice were protected from ischemia–reperfusion injury
of the heart [27,29] and brain [30,44], infarct size being reduced in
CyPD-null adults compared to wild-type or littermate controls.
These studies do corroborate the conclusions of previous studies
based on the use of CsA in ischemic isolated hearts [45] and in
infarcted patients [46], in brain damage by hypoglycemia [47],
hyperglycemia [48], middle cerebral artery occlusion [49,50], and
traumatic injury [51,52]. Ppif−/− mice also display resistance to
development of axonopathy in autoimmune encephalomyelitis [53]
and to disease progression after crossing with superoxide dis-
mutase 1 mutant mice [54], suggesting that CyPD-dependent (and
possibly PTP-dependent) mechanisms are critical in the neurode-
generative aspects of demyelinating and motor neuron diseases.
Ablation of CyPD substantially improved learning, memory, and
synaptic function, and alleviated decreased long-term potentiation
by the amyloid β peptide in a mouse model of Alzheimer's disease
[55].
Perhaps the best case involving CyPD in pathology in vivo is
represented by collagen VI diseases [56], a set of genetically heterog-
enous conditions that cause Bethlemmyopathy [57], Ullrich congenital
muscular dystrophy [58,59] andmyosclerosis [60]. The rodentmodel of
the disease (Col6a1−/− mice lacking collagen VI [61]) displays
mitochondrial alterations in affected muscles that could be cured with
CsA [62] orwith theCyP inhibitor Debio 025 [63], and Ppif−/− Col6a1−/−
mice lacking both CyPD and collagen VI became indistinguishable from
syngenic wild typemice [64], a clear indication that CyPD is involved in
the development of the disease downstream of the lack of collagen VI in
a process that is ampliﬁed by defective autophagy [65]. These results
match those obtained in patient cultures [66] and in a pilot clinical trial
with CsA [67], and in Ppif−/− Scgd−/− and Ppif−/− Lama2−/− mice
modeling sarcoglycan deﬁciency and congenital muscular dystrophy
due to lack of laminin, respectively [68].1.3. Modulation of the PTP by speciﬁc amino acid residues
Asmentioned above, themolecular nature of the PTP is not known,
yet we understand in some detail how the pore is modulated by key
pathophysiological effectors like voltage, matrix pH and oxidative
stress through speciﬁc Cys and His residues [8,10]. The PTP is voltage-
dependent in the sense that the open conformation is favored by
depolarization [69] while an acidic matrix pH locks the pore in the
closed conformation through reversible protonation of His residues
even in depolarized mitochondria [70,71]. The voltage-dependence in
turn is modulated by redox events through a dithiol-disulﬁde
interconversion at a matrix site that can be prevented by N-
ethylmaleimide (NEM) [72] or monobromobimane [73]. A second
redox-sensitive site whose oxidation increases the probability of PTP
opening has been identiﬁed based on the effects of the IMM-
impermeant reagent copper-o-phenanthroline (Cu(OP)2) [74]. Oxi-
dation of this site promotes PTP opening that was inhibited by
dithiotreitol (DTT) and β-mercaptoethanol but not monobromobi-
mane [74]. Conclusive evidence that this site is located on the outer
surface of the IMM rather than in the OMM was recently obtained in
digitonin mitoplasts, which displayed an identical inducing effect of
Cu(OP)2 as intact mitochondria [75].
Characterization of the PTP by chemical modiﬁcation of speciﬁc
residues has recently been pursued by a novel approach, i.e.
photoirradiation of mitochondria after treatment with porphyrins
[75–78]. The results of these experiments provided remarkable
information on the role and interactions of His and Cys residues in
PTP modulation, as well as on their topology, and suggested an
important role for the 18 kDa translocator protein (TSPO), formerly
known as the peripheral benzodiazepine receptor [79]. Before
covering in greater detail the picture emerging from these studies,
we will illustrate the basic principles of the photodynamic effect and
the mechanisms of phototoxicity and discuss the unique properties of
singlet oxygen (
1
O2) generated by speciﬁc porphyrins in discrete
mitochondrial domains.
2. The photodynamic effect
Photosensitization is a process induced by highly noxious
reactive species (free radicals and reactive oxygen species, ROS)
which are generated by molecules (called photosensitizers) after
they have adsorbed UV/visible light of appropriate wavelengths.
When oxygen is required for photosensitization to occur, the overall
process is deﬁned as “photodynamic.” Photosensitization can lead to
severe cell damage or death [80]. Nearly all organisms contain
potential photosensitizers (e.g., bilirubin, chlorophylls and porphyr-
ins), but under physiological conditions the photodynamic effect
does not occur because the concentration of these compounds is
low or because they are sequestered in complexes that inhibit
photosensitization reactions. Photosensitization from these natural
substances is only observed under extreme conditions such as the
porphyrias, a group of diseases that causes severe skin lesions
through overproduction of porphyrins. In addition to endogeneous
sensitizers, a broad variety of exogenous photosensitizers (present
in food, cosmetics, plants or their juices, chemicals, drugs, etc.) can
enter the body through ingestion, inhalation, injection or direct
contact with the skin or exposed mucosa, causing photodamage in
the presence of light.
Early last century scientists realized that the harmful effects of
photosensitizers could be a tool for medicine [81,82]. Since then, the
photochemical approach has primarily been developed as a
treatment for cancer and for ophthalmologic and dermatologic
disorders [83–88]. Although the term photodynamic therapy (PDT)
was only deﬁned at the beginning of the 20th century, this form of
therapy can be dated back over 3000 years. In one of India's sacred
books Atharava-Veda (1400 BC) a description is found of how
Fig. 1. Energy level diagram and photophysical and photobiological processes involving a photosensitizer. For explanation see text.
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ancient Egyptians cured with extracts of Ammi majus growing on the
banks of the Nile. The seeds of both plants contain psoralens, their
photoactive components [81,82]. The modern history of PDT started
with the observation that the combination of a chemical (acridine
red) and visible light had a lethal effect on the microorganism
Infusoria, a species of Paramecium [81,82]. The clinical potential of
this discovery was not explored for several decades also because of
the beginning of the antibiotic era. Today PDT (which inactivates
many classes of pathogens) is a promising tool to overcome the
problem of bacterial (multi-)drug resistance and to treat viral, fungal
and parasitic infections [87,89,90].Fig. 2. Simpliﬁed representation of the electronic conﬁgurations of molecular oxygen
lowest triplet and singlet states. The scheme depicts only π antibonding orbitals, for
further explanation see text.2.1. Mechanisms of phototoxicity
The physical processes involved in sensitizer phototoxicity are
illustrated in Fig. 1. The ground electronic state of the photosensitizer
is a singlet state (S0). On absorption of light of appropriate wavelength
(1) the photosensitizer is excited to one of its short-lived singlet
excited states, and rapid thermal relaxation leads to the lowest singlet
excited state (S1). The photosensitizer can then relax back to its
ground state by ﬂuorescence emission (2) and internal conversion
(3), or can undergo intersystem crossing (4) to its lowest triplet
excited state (T1). This latter transition is spin-forbidden, but a good
photosensitizer has a high probability of triplet-state formation after
excitation. The T1-state is sufﬁciently long-lived to take part in
chemical reactions, and therefore the photosensitizing action is
mostly mediated by the T1-state. The T1-photosensitizer can also
return to the S0-state by emitting phosphorescence (5). Activated
photosensitizers in the excited triplet state can induce photochemical
changes in a neighboring molecule via two competing pathways
(Fig. 1). If oxygen is present in the environment, the photosensitizer
can transfer its energy to form the highly reactive
1
O2 in a reaction
deﬁned as a type II mechanism [91]. The type I mechanism becomes
important at low oxygen concentration or in a more polar environ-
ment. In this process the photosensitizer reacts directly with organic
substrates, the solvent or another photosensitizer molecule via
electron or hydrogen transfer to yield free radicals. These species
are highly reactive and can easily interact with molecular oxygen to
generate intermediates such as the superoxide anion (O2−·), which
can convert to H2O2, the immediate precursor of the hydroxyl radical,
the most dangerous member of the ROS family [91–93]. Both type I
and type II reactions cause oxidation of cellular biomolecules.
Frequently they occur simultaneously, and the ratio depends onseveral parameters, the type of photosensitizer and the oxygen
concentration being the most important [91,93]. For most photo-
sensitizers employed in PDT, the type II photochemical reaction is the
dominant process [94,95].2.2. Singlet oxygen
In contrast to the vast majority of molecules, molecular oxygen in
its ground state has an electronic triplet conﬁguration with two
unpaired electrons occupying two degenerate π antibonding orbitals




these electrons have opposite spin. The
1
ΔgO2 form (noted for
simplicity as
1
O2) is involved in photosensitization, while
1∑gO2 is
too short-lived (10−11–10−9 s in solution) to be biologically relevant
[93,96]. Electrophilic
1
O2 is seeking electrons to ﬁll its vacant
molecular orbital, and it thus reacts readily with electron-rich
molecules. Targets for oxidation are lipids (cholesterol and phospho-
lipids), amino acids (Trp, Tyr, His) and nucleic acid bases (guanine and
guanosine) that have double bonds, as well as sulfur-containing
amino acids (Cys, Met) [95,96]. In biological systems proteins are the
main intracellular targets for
1
O2 owing to their abundance and fast
rates of reaction, which are two orders of magnitude faster than those
displayed with unsaturated lipids [97,98]. The reaction of
1
O2 with
proteins can result in multiple effects including oxidation of side-
chains, backbone fragmentation, dimerization/aggregation, unfolding
Fig. 3. Effect of increasing irradiation times on the Ca2+ retention capacity of HP-loaded
mouse liver mitochondria. CD1 mouse liver mitochondria (0.5 mg/ml) were incubated
for 2 min at 25 °C in a medium containing 250 mM sucrose, 10 mM Tris–Mops pH 7.4,
5 mM succinate–Tris, 1 mM Pi–Tris, 10 μM EGTA–Tris, 3 μM HP, 2 μM rotenone, 0.5 μg/
ml oligomycin, 0.5 μM Calcium Green-5N. After irradiation for the indicated periods of
time at a ﬂuence rate of 40 W/m2,mitochondriawere loadedwith a series of 10 μMCa2+
pulses at 1 min intervals. PTP opening was determined as the Ca2+ retention capacity
(CRC, expressed as the % of the CRC of non-irradiated organelles) measured at excitation
480 nm and emission 530 nm. The CRC decrease at high doses of light was prevented by
1 μM CsA (data not shown, see also Ref. [75]). Error bars refer to the mean±S.D. of four
experiments.
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tions in cellular handling and turnover [97].
1
O2 has unique features compared to other ROS. Being an
electronically excited state it is generally produced when exogenous
or endogenous photosensitizers absorb the appropriate wavelength of
visible or UV–radiation; in contrast, other ROS such as H2O2 and O2−·
are produced in cells during normal physiological processes or are
formed by activated neutrophils and macrophages. These “physio-
logical” ROS can readily interconvert, making it difﬁcult to discern
which ROS is responsible for a particular cellular response, while
1
O2
does not interconvert to other ROS. Finally, the lifetime of
1
O2 has an
inherent upper value (i.e. how long
1
O2 exists in the absence of
reactive molecules) which poses an upper limit to its mobility from
the site of generation. Based on the
1
O2 lifetime of~4 μs a maximal
diffusion radius of a mere~220 nm in water has been calculated [98].
After this period of time
1
O2 returns to the ground state and loses
reactivity by transferring its energy to the solvent. In contrast, other




O2 in homogeneous solutions is between 10−6 and
10−3 s [99]. This value is considerably shorter in cellular systems,
ranging from 100 ns in the lipid regions of membranes to 250 ns in
the cytoplasm. The shorter intracellular lifetime of
1
O2 indicates
efﬁcient quenching of this species by reaction with susceptible
intracellular targets (for a review see Ref. [93]). Due to the abundance
of these reactive molecules, the diffusion distance of
1
O2 in cells and
tissues has been estimated to be in the order of 0.01–0.02 μm [100–
102]. Given a cell diameter of 10–30 μm, it can be reasonably
assumed that the primary site of photodamage is also the site where
1
O2 has been generated. Thus, the intracellular localization of the
photosensitizer is the major determinant in dictating which
subcellular structures will be reached and attacked. Generally,
mitochondrial photosensitizers are able to induce apoptosis very
rapidly, lysosomal photosensitizers can elicit either a necrotic or an
apoptotic response, and plasmamembrane photosensitizers can lead
to cell rescue or initiate apoptosis and/or necrosis (for a review, see
Ref. [103]).
2.3. Porphyrins as photosensitizers
Porphyrins were identiﬁed in the mid-19th century, but it was
not until the early 20th century that they were used in Medicine.
Between 1908 and 1913 a number of photobiological experiments
were carried out with hematoporphyrin (HP), demonstrating how it
sensitized paramecia, erythrocytes, mice, and guinea pigs to light
[81,82]. The pioneering report of human photosensitization by
porphyrins was published in 1913 by Friedrich Meyer-Betz, who
injected himself with 200 mg of HP and reported swelling and
prolonged pain in light-exposed areas [82,104]. The subsequent
discovery of the tumor-localizing properties of porphyrins and of
the phototoxic effects on tumor tissues led to the development of
modern clinical PDT [105–110].
The “photoactive core” of porphyrin-based compounds is the
tetrapyrrolic macrocycle (porphine), while peripheral substituents
control drug biodistribution and pharmacokinetics. Tetrapyrroles
are naturally occurring pigments and vital constituents of oxida-
tion–reduction and oxygen transport-related proteins such as
hemoglobins, cytochromes, apoferritin, catalase, ferrichrome and
peroxidases. Within these proteins tetrapyrroles are not able to
induce photochemical reactions due to the presence of metal ions
(Fe3+, Al3+, Mg2+) which increase the probability of non-radiative
decay of the triplet state. Indeed, the most efﬁcient porphyrin-
based photosensitizers (free base porphyrins) lack coordinated
metal ions.
In the monomeric state free base porphyrins are potent photo-
sensitizers with long lifetimes and high quantum yields of tripletformation (ΦT~0.7–0.9) while aggregation decreases the probability
of photoexcitation. Because of the low energy gap between the triplet
states of tetrapyrroles and molecular oxygen, a large fraction of
triplets (0.7–1.0) leads to
1
O2 generation by energy transfer. Thus,
1
O2
is the predominant phototoxic species involved in porphyrin-
photosensitized processes with a quantum yield of
1
O2 production
(ΦΔ) between about 0.7 and 0.9 for carboxylic porphyrins [111].
Alternative pathways for oxygen activation by photoexcited porphyr-
ins (e.g. generation of O2−· by electron transfer) usually have an
efﬁciency lower than 0.1 [112].
Under the same experimental conditions, monomeric porphyrins
exhibit quite similar photophysical properties and photosensitizing
efﬁciency, independent of their chemical structure and the nature of
the surrounding environment [111,113]. In particular, the yield of
1
O2
is similar for monomeric porphyrins with various degrees of
hydrophobicity [111]. In spite of their similar basic structure and
photophysical characteristics, however, porphyrins in cells display a
wide range of activities even when they target the same organelle;
and small differences (e.g. of peripheral substituents) result in
different physicochemical properties that modulate the afﬁnity for
binding sites dictating uptake, subcellular distribution and therefore
the ﬁnal target of the photoprocess [111,114]. For these reasons a
clever use of porphyrins can yield a wealth of information on
biological processes.2.4. Mitochondria as targets of porphyrin photodynamic activity
Studies with porphyrin-loaded cells indicate that hydrophobic
porphyrins tend to concentrate in mitochondria, especially after
prolonged incubation [115]. Mitochondrial damage is a major determi-
nant of porphyrin phototoxicity [116–118] to which cells with few
mitochondria are refractory [119]. Several mitochondrial components
are affected by photoirradiation [115,116,119–121]. Light- and dose-
dependence studies using dicarboxylic porphyrins (mainly HP) indicate
that ATP synthesis is the ﬁrst function to be lost because the F0F1 ATP
synthase [115] and the adenine nucleotide translocator (ANT) [120] are
themost vulnerable
1
O2 targetswhereas respiration, Ca2+uptake,OMM,
matrix and intermembrane enzyme activities are more resistant in this
order.
Fig. 4. Effect of PP-like (DP, HP, PP) and PP-unrelated (CP, EP, UP) porphyrins on light-
dependent activation of the permeability transition. Wistar rat liver mitochondria
(0.5 mg/ml) were incubated for 2 min at 25 °C in a medium containing 250 mM
sucrose, 10 mM Tris–Mops, 5 mM succinate, 1 mM Pi–Tris, 10 μM EGTA–Tris, 0.5 μg/ml
oligomycin, 2 μM rotenone, pH 7.4 plus concentrations of each porphyrin giving a
loading of 1.2 nmol of porphyrin/mg of protein (see also Ref. [75]). Preparations were
then supplemented with 5 μM Ca2+ (a concentration not sufﬁcient to induce PTP
opening per se) and irradiated for the indicated times at a ﬂuence rate of 40 W/m2. The
PTwas followed as the change in 90° light scattering at 540 nm. Error bars represent the
mean±S.D. of three experiments. Ki values for porphyrins were taken from Ref. [123].
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at catalyzing cellular photodamage correlated closely with their
afﬁnities for the TSPO. Among a wide variety of porphyrins and
porphyrin-like compounds the most photoactive were dicarboxylic
porphyrins endowed with PP-like conﬁguration such as PP itself,Fig. 5. Photodynamic events mediated by porphyrins at PTP-regulating His and Cys residues.
TSPO. (B) Matrix-facing IMM porphyrin-binding sites are located in close proximity to cri
proximity to TSPO. In the dark, HP does not affect the structural properties of His- and Cys-co
Cys when PhAsO or Cu(OP)2 are added (omitted for clarity from the scheme, but see Refs. [75
generates
1
O2 in the proximity of critical His residues which undergo modiﬁcation and c
oxidation, thus resulting in PTP inhibition. (D) Irradiation with high light doses causes TSP
surface thiols by
1
O2, resulting in PTP opening. For further explanation see text.mesoporphyrin IX, deuteroporphyrin (DP) and HP, which bind TSPO
with nanomolar afﬁnities [123]. Such selectivity for PP-like porphyrins
has been ascribed to the major physiological role of TSPO to mediate
mitochondrial uptake of naturally occurring dicarboxylic porphyrins
such as PP, other hemeprecursors aswell as heme itself [123,124]. TSPO
is an 18 kDa OMM protein that may be located at junctional sites with
the IMM [124–126]. Such a localization could inﬂuence substrate
transfer between cytosolic and mitochondrial compartments, and
porphyrins with the highest afﬁnity for TSPO would be expected to
accumulate best. The notion of TSPOmediating porphyrin phototoxicity
was conﬁrmed by our recent results inmitoplasts [75] while it has been
challenged by other authors [127]. A key role of TSPO in controlling
mitochondrial internalization and photoactivity of porphyrins is
supported by the ﬁnding that high-afﬁnity ligands of TSPO (such as 1-
(2-chlorophenyl)-N-methyl-N-(1-methyl-propyl)-3-isoquinolinecar-
boxamide, PK11195, and 7-chloro-5-(4-chlorophenyl)-1,3-dihydro-1-
methyl-2H-1,4-benzodiazepin-2-one, Ro5-4864) as well as cholesterol,
prevent porphyrin-induced phototoxicity [128–131] probably by
inhibiting translocation of porphyrins into mitochondria [129,131]
(see also the following paragraphs).
3. Light on the PTP
In 1997 Salet et al. [76] and later Moreno et al. [77] exploited the
photodynamic effect to study the PT. This approach provided detailed
information on critical residues regulating the PT and helped to
understand the role of IMM and OMM in PTPmodulation [75–78]. The
ﬁrst observation was that a short photoirradiation of mitochondria(A) Porphyrins with PP-like conﬁguration are transported inside mitochondria through
tical His residues, and additional binding sites are adjacent to external thiols in close
ntaining domains, and PTP can open through selective oxidation of internal or external
,78]). (C) After mitochondrial irradiation with moderate light doses, photoactivated HP
ause a structural rearrangement of the internal dithiol which can no longer undergo
O-dependent photoactivation of porphyrins in the OMM leading to oxidation of IMM
487F. Ricchelli et al. / Biochimica et Biophysica Acta 1807 (2011) 482–490loaded with HP caused inactivation of the ANT, yet mitochondria
retained their ability to form a proton electrochemical gradient, and
accumulated Ca2+ and Pi at the same rate as non-irradiated
mitochondria. Strikingly, the oxidative effects of photodynamic action
prevented opening of the PTP, which is normally induced by Ca2+ plus
Pi, in the ﬁrst example of pore inactivation by an oxidant [76], which is
at variance with what is generally observed under oxidizing
conditions [132–135]. The inactivating effect could be traced to
photomodiﬁcation of matrix His residues (the direct target of
1
O2) by
vicinal porphyrin; this in turn lowered the reactivity of critical dithiols
whose oxidation (e.g. by diamide) causes opening of the PTP [72].
Irradiation of HP-loaded mitochondria thus represents an example of
site-selective inactivation of discrete pore functional domains
comprising critical His and Cys residues in close structural and
functional correlation [76].
The next ﬁnding was that irradiation with higher light doses
caused instead opening of the PTP, which was attributed to
photooxidation of IMM external thiols [75,78]. The effect of light
dose on the Ca2+ retention capacity (CRC) of mouse liver mitochon-
dria (a sensitive measure of the propensity of the PTP to open) is
illustrated in Fig. 3. The initial increase of CRC (i.e. pore desensitiza-
tion) was offset by a sharp decrease as the irradiation time increased.
Since at high light dose the previously identiﬁed His and Cys residues
have already been inactivated by matrix porphyrin, reactivation must
depend on a different porphyrin site, which is speciﬁcally contributed
by the OMM through TSPO [75]. The properties of this site are
illustrated in the experiments of Fig. 4, where irradiation times of
more than 60 s were applied to rat liver mitochondria preincubated
with concentrations of PP, DP, HP, coproporphyrin III (CP), uropor-
phyrin I (UP) and etioporphyrin (EP) yielding an identical loading of
1.2 nmol of porphyrin×mg−1 of protein. The relative potency of PP-
related porphyrins at sensitizing the PTP (measured here as the rate of
mitochondrial permeabilization to sucrose) matched their afﬁnity for
TSPO, as based on the Ki displayed by each porphyrin for inhibition of
binding of PK11195, a classical ligand of TSPO (see also Ref. [136]). The
process of PTP activation was speciﬁc to porphyrins characterized by a
PP-like conﬁguration that bind TSPO with nanomolar afﬁnity (PP, DP
and HP), whereas PP-unrelated porphyrins such as tetracarboxylic CP,
octacarboxylic UP and EP, which lacks carboxylic groups, were
ineffective (Fig. 4 and Ref. [75]). It is also remarkable that
porphyrin-mediated PTP photoactivation is suppressed (results not
shown) by low concentrations of the high-afﬁnity, porphyrin-
competitive TSPO ligand FGIN1-27 [136].
The regulatory role of the OMM and TSPO on the PTP was
conﬁrmed by a study of mitoplasts prepared with digitonin
concentrations that allowed selective removal of the OMM without
interfering with mitochondrial energy-linked functions [75]. Like
mitochondria, mitoplasts readily underwent PTP opening following
Ca2+ uptake in a CsA-sensitive process, but major differences
emerged in PTP regulation by ligands of TSPO. In mitoplasts the PTP
could not be activated by photooxidation after treatment with
dicarboxylic porphyrins endowed with PP conﬁguration, and mito-
plasts became resistant to the PTP-inducing effects of selective ligands
of TSPO [75].
4. Summary and conclusions
In photosensitization of biological materials by
1
O2 the photo-
damage is strictly limited to the immediate surroundings of the
sensitizer because of the short diffusion distance and high reactivity of
the photogenerated species. This peculiar oxidation mechanism
provided novel information on residues regulating the PTP. Studies
with this approach, whose results are summarized in Fig. 5, allowed to
characterize the PTP-modulating properties of sites which exhibit
different sensitivity towards oxidation by photoactivated porphyrins.
Under basal conditions (Fig. 5A) the PTP favors the closed conforma-tion. Porphyrins transported through TSPO are transferred to matrix,
IMM and OMM sites, but in the absence of photoirradiation they do
not affect the reactivity and pore-modulating properties of internal
(matrix-exposed) and external cysteines located on the outer surface
of the IMM [75] (Fig. 5B). Photoirradiation for short periods of time
hits the most vulnerable site, which comprises matrix-exposed His
and causes a secondary drop of reactivity of internal Cys, thus
stabilizing the PTP in the closed conformation (Fig. 5C). Inactivation of
internal Cys by His photodegradation allowed to establish the role of
(i) external regulatory Cys, which can still undergo oxidation and thus
increase the probability of PTP opening and (ii) of TSPO, which is
essential for reactivation of the PTP by high light doses, an effect
mediated in part at least by oxidation of regulatory thiols on the outer
surface of the IMM (Fig. 5D).
TSPO thus fulﬁlls a dual role in PTP modulation (i) as a transport
protein for PTP-active compounds that are transferred to their PTP
regulatory site(s) in the IMM or in the matrix and (ii) as a PTP
regulatory protein when it binds its selective ligands like porphyrins.
TSPO belongs to a family of ubiquitous proteins conserved from
bacteria to mammals that bind small drugs, cholesterol, and
porphyrins [79]. Consistent with its role in steroid hormone synthesis,
in mammals TSPO is highly expressed in the adrenal cortex [137,138],
and its inactivation induces an early embryonic-lethal phenotype in
the mouse [139]. Establishing a role for TSPO in PTP modulation,
which was also made possible by the unique features of the
photodynamic effect, holds great promise for our continuing studies
on the nature of the PTP, and on the development of drugs that can
modulate its probability of opening.
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